Streetbeat News

SXTP

60 Degrees Pharmaceuticals, Inc.

Industry

Biotechnology

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Open

1.07

Mkt cap

1.8M

Volume

93K

High

1.08

P/E Ratio

-0.62

52-wk high

18.36

Low

0.94

Div yield

N/A

52-wk low

0.70

During Friday's intraday session, several healthcare stocks experienced significant movements. Jin Medical International (ZJYL) saw a substantial rise of 85.2%, while Karuna Therapeutics (KRTX) increased by 47.07%. Conversely, AlloVir (ALVR) plummeted by 65.7%. Other notable movers included IMAC Hldgs (BACK), PureTech Health (PRTC), HeartBeam (BEAT), Neumora Therapeutics (NMRA), Cyclacel Pharmaceuticals (CYCC), 60 Degrees (SXTP), Nanobiotix (NBTX), Trinity Biotech (TRIB), and GRI Bio (GRI).

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 5:31 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Karuna Therapeutics (KRTX) saw a substantial increase of 47.9%, while AlloVir (ALVR) faced a sharp decline of 57.5%. Other notable gainers include Senti Biosciences (SNTI), SenesTech (SNES), Galecto (GLTO), TC BioPharm (TCBP), and Reviva Pharmaceuticals (RVPH). Conversely, 60 Degrees (SXTP), Nanobiotix (NBTX), DMK Pharmaceuticals (DMK), Oncternal Therapeutics (ONCT), and ThermoGenesis Holdings (THMO) were among the losers.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 1:07 pm

In Thursday's after-market session, several healthcare stocks experienced significant movements. NuCana, Galecto, Ensysce Biosciences, Atara Biotherapeutics, 60 Degrees, and PetVivo Holdings saw their shares rise, with increases ranging from 7.75% to 15.6%. Conversely, Oncternal Therapeutics, Altamira Therapeutics, Nuwellis, DMK Pharmaceuticals, ASLAN Pharma, and SCWorx saw their shares decline, with decreases ranging from 5.65% to 12.7%. These movements reflect changes in investor sentiment and market dynamics for these small-cap companies.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 9:31 pm

CarMax, Inc. (NYSE:KMX) shares rose by approximately 8% following its quarterly earnings report, which showed an EPS of $0.52, surpassing the consensus estimate of $0.44, despite a 5.5% year-on-year sales decline. Other stocks experienced significant movements in Thursday's mid-day session, with various companies reporting investments, acquisitions, and regulatory updates that influenced their stock prices.

Portfolio Pulse from Avi Kapoor

December 21, 2023 | 6:01 pm

BlackBerry Limited (NYSE:BB) shares dropped over 5% in pre-market trading despite reporting Q3 earnings of 1 cent per share, beating the expected loss of 3 cents per share. The company anticipates Q4 revenue between $150 million to $159 million. Other stocks experienced significant movements in pre-market trading, with Infrared Cameras Holdings Inc. (NASDAQ:MSAI) and Mobile Global Esports Inc. (NASDAQ:MGAM) among the top gainers, while Polished.com Inc. (NYSE:POL) and Nogin, Inc. (NASDAQ:NOGN) were among the biggest losers.

Portfolio Pulse from Avi Kapoor

December 21, 2023 | 12:46 pm

In Monday's after-market session, several healthcare stocks experienced significant movements. Tharimmune (THAR) saw a 19.0% increase, while Amarin Corp (AMRN) rose by 11.63%. Travere Therapeutics (TVTX) increased by 8.42%, iBio (IBIO) by 6.29%, Motus GI Holdings (MOTS) by 5.74%, and Burning Rock Biotech (BNR) by 5.0%. On the downside, Cognition Therapeutics (CGTX) fell by 12.2%, Acrivon Therapeutics (ACRV) by 12.03%, Virpax Pharmaceuticals (VRPX) by 11.75%, Inhibikase Therapeutics (IKT) by 8.81%, 60 Degrees (SXTP) by 6.74%, and Gossamer Bio (GOSS) by 6.07%.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 9:31 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. Redhill Biopharma (RDHL) saw a sharp increase of 118.7%, while Tharimmune (THAR) and Apollomics (APLM) rose by 39.13% and 33.37%, respectively. Conversely, Impel Pharmaceuticals (IMPL) and Nuwellis (NUWE) saw declines of 17.7% and 16.69%. Other notable movers included 60 Degrees (SXTP), Sunshine Biopharma (SBFM), Olema Pharmaceuticals (OLMA), Envoy Medical (COCH), Kura Oncology (KURA), SenesTech (SNES), and Kiora Pharmaceuticals (KPRX).

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 1:07 pm

Gap Inc. (GPS) shares surged by approximately 17% in pre-market trading following the release of their Q3 financial results, which surpassed analyst expectations. The company reported earnings of $0.59 per share against an expected $0.18, with sales of $3.767 billion beating the $3.610 billion estimate. Other stocks also showed significant pre-market movements, with notable gainers including Safe and Green Development Corporation (SGD), Syntec Optics Holdings (OPTX), and Mural Oncology (MURA), among others. Conversely, several stocks experienced declines, such as Bone Biologics Corporation (BBLG), ChargePoint Holdings (CHPT), and Alpha Technology Group Limited (ATGL).

Portfolio Pulse from Lisa Levin

November 17, 2023 | 1:25 pm

Shapeways Holdings, Inc. (SHPW) shares dropped by approximately 20% following the release of disappointing financial results, with an adjusted loss per share and quarterly sales both missing market expectations. Other stocks experienced significant movement in Wednesday's mid-day session, with various companies reporting financial results, FDA designations, and potential acquisition interest.

Portfolio Pulse from Lisa Levin

November 15, 2023 | 7:04 pm

60 Degrees Pharmaceuticals has been granted a Type C meeting by the FDA to discuss the development of the Tafenoquine regimen of Arakoda for hospitalized babesiosis patients. The meeting is scheduled for January 15, 2024.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 12:40 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.